(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of 5.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Xencor's revenue in 2026 is $150,132,000.On average, 16 Wall Street analysts forecast XNCR's revenue for 2026 to be $8,814,194,189, with the lowest XNCR revenue forecast at $2,856,204,529, and the highest XNCR revenue forecast at $22,065,834,921. On average, 12 Wall Street analysts forecast XNCR's revenue for 2027 to be $9,399,760,034, with the lowest XNCR revenue forecast at $0, and the highest XNCR revenue forecast at $21,564,533,429.
In 2028, XNCR is forecast to generate $13,050,977,314 in revenue, with the lowest revenue forecast at $4,543,062,627 and the highest revenue forecast at $29,557,507,224.